Pharming Group N.V.

NasdaqGM:PHAR Stock Report

Market Cap: US$608.2m

Pharming Group Future Growth

Future criteria checks 3/6

Pharming Group is forecast to grow earnings and revenue by 57.2% and 7.9% per annum respectively. EPS is expected to grow by 53.8% per annum. Return on equity is forecast to be 10.9% in 3 years.

Key information

57.2%

Earnings growth rate

53.8%

EPS growth rate

Biotechs earnings growth27.5%
Revenue growth rate7.9%
Future return on equity10.9%
Analyst coverage

Low

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Pharming's rare immunodeficiency disorder drug gets FDA priority review

Sep 28

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

Aug 01

Earnings and Revenue Growth Forecasts

NasdaqGM:PHAR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274044028355
12/31/202634986165
12/31/2025311-7-855
12/31/2024281-11235
9/30/2024286-1800N/A
6/30/2024278-13-6-6N/A
3/31/2024258-1118-2N/A
12/31/2023245-113-17N/A
9/30/2023219-22-4-24N/A
6/30/2023206-165-15N/A
3/31/2023202-2-3-1N/A
12/31/2022206142022N/A
9/30/2022204302533N/A
6/30/2022202211526N/A
3/31/2022202111731N/A
12/31/2021199162138N/A
9/30/2021200222943N/A
6/30/2021200314052N/A
3/31/2021202375970N/A
12/31/2020212386884N/A
9/30/2020212447085N/A
6/30/2020202465993N/A
3/31/2020202425384N/A
1/1/2020189414974N/A
9/30/2019175384870N/A
6/30/2019175345963N/A
3/31/2019158295457N/A
12/31/2018155294246N/A
9/30/2018152-295763N/A
6/30/2018138-44N/A61N/A
3/31/2018128-80N/A52N/A
12/31/2017108-91N/A46N/A
9/30/201776-53N/A14N/A
6/30/201747-47N/A-6N/A
3/31/201731-21N/A-13N/A
12/31/201617-18N/A-11N/A
9/30/201612-16N/A-18N/A
6/30/201612-15N/A-18N/A
3/31/201613-14N/A-18N/A
12/31/201512-11N/A-19N/A
9/30/2015298N/A-3N/A
6/30/2015279N/A-1N/A
3/31/20152310N/A-3N/A
12/31/201426-7N/A-3N/A
9/30/20146-29N/A-19N/A
6/30/20146-35N/A-16N/A
3/31/201411-35N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PHAR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PHAR is expected to become profitable in the next 3 years.

Revenue vs Market: PHAR's revenue (7.9% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: PHAR's revenue (7.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PHAR's Return on Equity is forecast to be low in 3 years time (10.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/28 23:58
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH
Joseph PantginisH.C. Wainwright & Co.